Federated Hermes’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.31M | Buy |
203,930
+1,145
| +0.6% | +$7.34K | ﹤0.01% | 1053 |
|
|
2025
Q1 | $718K | Buy |
202,785
+469
| +0.2% | +$1.66K | ﹤0.01% | 1199 |
|
|
2024
Q4 | $765K | Buy |
202,316
+16,030
| +9% | +$60.6K | ﹤0.01% | 1193 |
|
|
2024
Q3 | $604K | Buy |
186,286
+7,512
| +4% | +$24.3K | ﹤0.01% | 1288 |
|
|
2024
Q2 | $340K | Buy |
178,774
+2,791
| +2% | +$5.3K | ﹤0.01% | 1394 |
|
|
2024
Q1 | $500K | Buy |
175,983
+73,483
| +72% | +$209K | ﹤0.01% | 1321 |
|
|
2023
Q4 | $1.51M | Sell |
102,500
-221,760
| -68% | -$3.26M | ﹤0.01% | 1022 |
|
|
2023
Q3 | $5.94M | Sell |
324,260
-1,204,740
| -79% | -$22.1M | 0.02% | 654 |
|
|
2023
Q2 | $33M | Sell |
1,529,000
-317,117
| -17% | -$6.84M | 0.08% | 279 |
|
|
2023
Q1 | $54.2M | Buy |
1,846,117
+231,272
| +14% | +$6.79M | 0.14% | 180 |
|
|
2022
Q4 | $59.7M | Buy |
1,614,845
+285,845
| +22% | +$10.6M | 0.17% | 155 |
|
|
2022
Q3 | $37.4M | Buy |
+1,329,000
| New | +$37.4M | 0.11% | 228 |
|